Close rivalries among US medical affairs teams for leading injectable type 2 diabetes mellitus therapies. Will your team come out on top?
In the US, three medical affairs teams for leading injectable therapies for type 2 diabetes mellitus are duking it out for top spot, with only 2 points separating them. What could teams do to move further ahead or close the gap even more? And can other teams get into the mix of the top 3? 100 diabetologists and primary care physicians provide insights on several medical affairs teams, and opinions are mixed. Will targeting improvements in certain areas be enough to put your team ahead of the competition?
Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Type 2 Diabetes Mellitus [Injectables] (US) . This report, which covers 12 major injectable therapies in the type 2 diabetes market from Sanofi, Eli Lilly, Novo Nordisk, and GlaxoSmithKline, including Adlyxin, Humalog, Lantus, NovoLog, Ozempic, Ryzodeg, Tanzeum, Toujeo, Tresiba, Trulicity, Victoza and Xultophy, provides handy graphs and charts which show at a glance how each team is performing across 12 key medical affairs activities, and where they need to improve:
- How diabetologists and primary care physicians rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important.
- How, and how often diabetologists and primary care physicians want to meet with your team.
- What you can do to improve your medical affairs services.
That’s actionable information you can use to turn your team into one that doctors rely on.
Interested in the European market? Click here to see the EU5 Edition.
- Can other teams get into the top 3? With only 2 points separating the top 3 teams, there’s more than enough room for another team to take the initiative and come out top; but what do they need to do?
- Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions, with nearly all teams tasked with improving in this area.
- Huge variations in activity. In the past six months, only 4 of 12 teams interacted with more than 70 percent of doctors surveyed, and the least active teams saw no more than 24 percent of them.
- In person or via digital channels? The report reveals how physicians want to interact with type 2 diabetes medical affairs teams. Use this information to refine your medical affairs strategy.
Insight into Medical Affairs Teams for 12 Injectable Type 2 Diabetes Mellitus Treatments
- Adlyxin (lixisenatide; Sanofi)
- Humalog (insulin lispro; Eli Lilly)
- Lantus (insulin glargine; Sanofi)
- NovoLog (insulin aspart; Novo Nordisk)
- Ozempic (semaglutide; Novo Nordisk)
- Ryzodeg (insulin degludec/insulin aspart; Novo Nordisk)
- Tanzeum (albiglutide; GlaxoSmithKline)
- Toujeo (insulin glargine; Sanofi)
- Tresiba (insulin degludec; Novo Nordisk)
- Trulicity (dulaglutide; Eli Lilly)
- Victoza (liraglutide; Novo Nordisk)
- Xultophy (insulin degludec/liraglutide; Novo Nordisk)
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
Does your medical affairs team deliver?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
What needs improvement?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
Based on Interviews with Practicing Doctors
We surveyed 100 US diabetologists, chosen from the largest community of validated physicians in the world.
- Have been practicing for between 3 and 35 years
- See at least 5 patients with type 2 diabetes mellitus in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months
We conducted the survey between July 2-5, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.